微环境诱导的可编程纳米疗法可以恢复线粒体功能障碍,以改善非酒精性脂肪肝疾病
Jun Zhang1, Wenyi Yang1, Yue Zhu1
1Key Laboratory of Endocrine Glucose & Lipids Metabolism and Brain Aging, Ministry of Education; Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, China; Shandong Key Laboratory of Endocrinology and Lipid Metabolism, Jinan, Shandong, 250021, China; Jinan Key Laboratory of Translational Medicine on Metabolic Diseases, Shandong Institute of Endocrine and Metabolic Diseases, Endocrine and Metabolic Diseases Hospital of Shandong First Medical University, Jinan, Shandong 250012, China; Shandong Engineering Laboratory of Prevention and Control for Endocrine and Metabolic Diseases, Jinan, Shandong, 250021, China.
研究人员开发了一种新型纳米治疗药物,该药物向肝细胞线粒体,用于治疗非酒精性脂肪性肝病 (NAFLD). 这种可编程治疗恢复了线粒体功能,并改善了NAFLD模型中的肝脏健康.
科学领域:
- 生物医学工程 生物医学工程
- 纳米医学是一种纳米医学.
- 肝病学 肝病学是一种肝病学.
背景情况:
- 非酒精性脂肪性肝病 (NAFLD) 是一种与线粒体功能障碍相关的流行代谢障碍.
- 线粒体透性过渡孔 (mPTP) 的开放是NAFLD进展的关键因素.
- 恢复线粒体功能为NAFLD提供了治疗途径.
研究的目的:
- 设计和开发一种微环境诱导的可编程纳米疗法,用于NAFLD治疗.
- 为了恢复线粒体功能和改善NAFLD的进展.
- 为了研究向肝细胞线粒体用于NAFLD治疗的潜力.
主要方法:
- 通过组装德克斯移植的银河糖 (Dex-Gal) 和Dex-triphenylphosphine (Dex-TPP) 来制备纳米疗法.
- 利用银河糖用于肝细胞特异性吸收和TPP用于溶酶体逃逸和线粒体向.
- 在实验室 (HepG2细胞) 和体内 (NAFLD小鼠模型) 评估纳米治疗疗效.
主要成果:
- 纳米疗法证明了肝细胞特异性吸收和成功的溶酶体逃逸.
- 试验室研究显示,通过抑制mPTP开放和减少活性氧物种,线粒体功能得到改善.
- 在体内研究证实了NAFLD小鼠的肝脏积累,线粒体自的恢复和改善的葡萄糖/脂质代谢.
结论:
- 一种新的微环境诱导的纳米治疗药物有效地准肝脏线粒体来治疗NAFLD.
- 纳米治疗策略在治疗NAFLD和其他线粒体相关疾病方面表现有前途.
- 这种方法提供了一种新的级联策略,用于精确地在现场向肝脏线粒体输送药物.
更多相关视频
08:15Exploring Mitochondrial Energy Metabolism of Single 3D Microtissue Spheroids Using Extracellular Flux Analysis
Published on: February 3, 2022
08:20Investigating the Protective Effects of Platycodin D on Non-Alcoholic Fatty Liver Disease in a Palmitic Acid-Induced In Vitro Model
Published on: December 2, 2022
